Endocrine Society Welcomes European Commission’s Chemical Strategy

The Endocrine Society welcomed the European Commission’s new Chemical Strategy for Sustainability and its measures to protect the public from endocrine-disrupting chemicals. The communication was released Wednesday as part of the European Green Deal. 

The strategy is designed to be the foundation for the biggest update to Europe’s chemical regulations in more than a decadeThe chemical strategy commits to a hazard identification for endocrine-disrupting chemicals (EDCs), including strict measures to prevent them from being used in consumer products. In addition, the strategy calls for stricter data requirements for EDCs across all relevant legislation and to accelerate the development and adoption of better test methods. 

“We are pleased to see the European Commission has taken this significant first step towards further protecting the public from EDC exposure with its new chemical strategy. We now need further details and concrete actions to protect public health and minimize consumers’ exposure to these hazardous chemicals.” – Barbara Demeneix, BSc, PhD, DSc, chair of the Society’s Endocrine-disrupting Chemicals Advisory Group

“EDCs are linked to serious health problems, such as infertility, diabetes, obesitycancer, and issues with brain development,” says Barbara Demeneix, BSc, PhD, DScchair of the Society’s Endocrine-disrupting Chemicals Advisory Group. “We are pleased to see the European Commission has taken this significant first step towards further protecting the public from EDC exposure with its new chemical strategy. We now need further details and concrete actions to protect public health and minimize consumers’ exposure to these hazardous chemicals.”  

The Commission also committed to introducing provisions for evaluating unintentional mixtures and will assess how best to address combination effects in the future. 

In addition, the chemical strategy prioritizes control measures for poly- and perfluoroalkyl substances (PFAS) and address them with a group approachThese manmade EDCs have leached into waterways and foods, and they can persist in the environment as well as our bodies. PFAS exposure is linked to health problems such as high cholesterol, disrupted thyroid function, and altered immune response. 

The Society has dedicated years to pressing for science-based policies to regulate EDCs, which mimic, block, or otherwise interfere with the body’s hormones. We are pleased the European Commission has announced its intention of adopting a hazard-based approach to regulating these harmful chemicals. However, the practical features and implementation steps will be important, and the Society urges the Commission to clarify these details to permit concrete actions without further delay.  

EDCs are commonly found throughout our environment in consumer products, food containers, personal care products, pesticides, and furniture. EDCs contribute to serious health problems such as diabetes, obesity, neurodevelopmental disorders, and reproductive problems. Children, unborn children, and adolescents’ developing bodies are particularly vulnerable to exposures.  

series of economic analyses found EDC exposures may be costing the EU upwards of €157 billion ($177 billion) a year. Society experts led the effort to quantify the public health impact of EDCs on the economy.  

The Endocrine Society will continue to monitor progress on legislative proposals to ensure that they are effective in minimizing exposure to EDCs.   

You may also like

  • Webinar Will Examine Concerns Around Compounding Anti-Obesity Medications

    Endocrine Society to host virtual Science Writers Conference Nov. 14 Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications. Endocrine Society experts will discuss the importance of prescribing FDA-approved medications to treat obesity during the Society’s Virtual Science Writers Conference on November 14. What:…

  • Bianco Named Vice President and Vice Provost for Research, Chief Research Officer at UTMB

    Antonio Bianco, MD, PhD, has joined the University of Texas Medical Branch (UTMB) as vice president and vice provost, research, and chief research officer, effective Sept. 1. A renowned physician-scientist, scholar, and research leader, Bianco possesses an impressive academic career that includes influential contributions to the field of thyroid diseases and an enduring commitment to…